Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan roll-over extension study in paroxysmal nocturnal hemoglobinuria
NL-OMON56127Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of iptacopan monotherapy. Started Jan 2022; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON56127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56127.